Online citations, reference lists, and bibliographies.
← Back to Search

Malignant Pleural Mesothelioma: A Single-center Experience In Turkey

A. Sezer, A. Sümbül, H. Abali, H. Mertsoylu, Ö. Özyılkan
Published 2014 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Background Malignant pleural mesothelioma is a rare lethal malignancy caused by asbestos exposure. It is more frequently seen in certain regions in Turkey. In this retrospective study, we aimed to analyse demographic, clinical, and pathological data and treatment-related features in 54 patients. Material/Methods The study included 54 patients diagnosed with malignant mesothelioma that were followed and treated. Results Of the 54 patients, 34 (55.6%) were male. The median age in men and women were 60.3 (38.2–77.2) and 65.8 (37.7–77.5) years, respectively. In 35 (64.8%), exposure to asbestosis was present. Epithelial type was found in 27 (50.0%), followed by mixed type in 7 (13.0%) patients, and in 20 (37.0%) patients the subtype could not be determined. The disease was staged as IV in 37 (68.5%) patients. In 28 patients (51.9%), it was right-sided and in 1 (1.9%) it was bilateral. The most frequent metastatic sites (in decreasing order) were lungs, mediastinum, diaphragm, liver, and thoracal wall. Of the 54 patients, 36 (66.6%) received 1st-line chemotherapy and 20 (37%) 2nd-line chemotherapy. Eighteen patients (33.3%) received radiotherapy; 11 (20.3%) with palliative intention and 7 (12.9%) with curative intention. Median overall survival (OS) was 12.03 months (95% CI 7.2–16.8). OS was not affected by sex (p=0.32), smoking history (p=0.51), alcohol consumption (p=0.36), family history (p=0.67), pleural effusion presence (p=0.80), operation (p=0.14), clinical stage (p=0.072), symptom at presentation (p=0.66), having mixed type histology (p=0.079), asbestos exposure (p=0.06), and type of 1st-line chemotherapy (p=0.161). On the contrary, it may be positively affected by good ECOG PS (0–1) (p<0.01), age below 65 (p=0.03), left-sided disease (p=0.01), receiving chemotherapy (p<0.01), having unilateral pleural effusion (p=0.018), and type of 2nd-line chemotherapy (p=0.025). Conclusions OS of our patients was better than that found in the literature, seeming to be positively affected by early stages, better ECOG PS, age below 65 years, left side involvement, and having second-line chemotherapy with cisplatin-gemcitabine or 3M. Overall treatment success seems to be comparable to what is currently expected.
This paper references
10.1378/CHEST.103.4_SUPPLEMENT.373S
Natural history and epidemiology of malignant mesothelioma.
K. Antman (1993)
10.1016/j.athoracsur.2009.12.041
Therapeutic surgery for nonepithelioid malignant pleural mesothelioma: is it really worthwhile?
B. Balduyck (2010)
10.1200/JCO.1998.16.1.145
Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.
D. Curran (1998)
10.1016/J.EJCA.2005.04.047
Incidence of pleural mesothelioma in Liguria Region, Italy (1996-2002).
V. Gennaro (2005)
10.1016/S0954-6111(99)90318-9
Environmental asbestos exposure and malignant pleural mesothelioma.
M. Metintas (1999)
10.1016/S1556-0864(15)31583-5
Induction Chemotherapy, Extrapleural Pneumonectomy, and Postoperative High-Dose Radiotherapy for Locally Advanced Malignant Pleural Mesothelioma: A Phase II Trial
R. Flores (2006)
10.1111/j.1349-7006.2009.01336.x
Genomic abnormalities and signal transduction dysregulation in malignant mesothelioma cells
Y. Sekido (2010)
10.1136/thx.35.8.564
Pleural calcification, pleural mesotheliomas, and bronchial cancers caused by tremolite dust.
S. Yazicioglu (1980)
Latent period for malignant mesothelioma of occupational origin.
B. Lanphear (1992)
10.1002/1097-0142(19861001)58:7<1540::AID-CNCR2820580727>3.0.CO;2-5
Diffuse malignant mesothelioma of pleura: Diagnosis and survival in 92 cases
V. Adams (1986)
An epidemiological study in an Anatolian village in Turkey environmentally exposed to tremolite asbestos.
L. Çöplü (1996)
Sağlık Bakanlığı Kanserle Savaş Dairesi Başkanlığı (Epidemiyoloji ve Koruma Şube Müdürlüğü)
S Eser (2004)
10.1378/CHEST.113.3.723
Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.
J. Herndon (1998)
10.1002/cncr.22309
The risk of secondary malignancies over 30 years after the treatment of non‐hodgkin lymphoma
L. Brown (2006)
10.1016/j.lungcan.2008.08.013
Malignant peritoneal mesothelioma-Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent.
G. Cartenì (2009)
10.1038/sj.bjc.6602307
The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050
J. Hodgson (2005)
10.1136/THX.52.6.507
Malignant mesothelioma in south east England: clinicopathological experience of 272 cases.
D. Yates (1997)
Malignant pleural mesothelioma due to environmental mineral fiber exposure in Turkey
ZT Selçuk (1992)
10.1378/CHEST.107.6_SUPPLEMENT.345S
Mesothelioma and radical multimodality therapy: who benefits?
D. Sugarbaker (1995)
10.1200/JCO.2008.20.3943
Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.
L. Krug (2009)
10.1159/000056289
Incidence of Malignant Pleural Mesothelioma due to Environmental Asbestos Fiber Exposure in the Southeast of Turkey
A. Şenyiğit (2000)
10.1378/CHEST.99.1.191
New developments in asbestos-induced pleural disease.
D. Schwartz (1991)
Epidemiyoloji ve Koruma Şube Müdürlüğü) Nüfus tabanlı kanser kayıt merkezleri veri havuzu: sekiz il, 2004-2006 değerlendirilmesi
S Eser (2011)
10.1067/MTC.2001.116560
A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
V. Rusch (2001)
AU: Malign pleural mesothelioma in Turkey, 2000–2002
S Emri (2004)
10.1016/J.LUNGCAN.2004.04.009
Malignant pleural mesothelioma in Turkey, 2000-2002.
S. Emri (2004)
10.1038/NM0897-913
The retinoblastoma gene family pRb/p105, p107, pRb2/p130 and simian virus-40 large T-antigen in human mesotheliomas
A. Luca (1997)
10.1111/j.1365-2559.2008.03178.x
Problems in mesothelioma diagnosis
Bruce Addis (2009)
10.1016/J.ATHORACSUR.2004.05.007
Pleural biopsy: a reliable method for determining the diagnosis but not subtype in mesothelioma.
R. Bueno (2004)
A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant mesothelioma
VW Rusch (2001)
10.1038/sj.bjc.6600505
A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma
A. Nowak (2002)
10.1016/J.EJSO.2004.08.014
Improved survival with VATS pleurectomy-decortication in advanced malignant mesothelioma.
J. Halstead (2005)
10.1378/CHEST.123.2.551
Surgical treatment of malignant pleural mesothelioma: a review.
S. van Ruth (2003)
10.1378/CHEST.102.3.790
Malignant pleural mesothelioma due to environmental mineral fiber exposure in Turkey. Analysis of 135 cases.
Z. Selçuk (1992)
10.1016/J.ATHORACSUR.2005.06.014
Extended surgical staging for potentially resectable malignant pleural mesothelioma.
D. Rice (2005)
Sağlık Bakanlığı Kanserle Savaş Dairesi Başkanlığı ( Epidemiyoloji ve Koruma Şube Müdürlüğü ) . Nüfus tabanlı kans - er kayıt merkezleri veri havuzu : sekiz il , 2004 - 2006 değerlendirilmesi
S Eser
Malign pleural mesothelioma in Turkey
S Emri (2000)
10.1200/JCO.2008.19.8523
Malignant pleural mesothelioma.
A. Tsao (2009)
10.6004/JNCCN.2012.0006
[Malignant pleural mesothelioma].
Q. Kong (1983)
10.1159/000056290
Malignant Pleural Mesothelioma Caused by Environmental Exposure to Asbestos in the Southeast of Turkey: CT Findings in 117 Patients
A. Şenyiğit (2000)
10.1179/oeh.2004.10.1.26
Malignant Pleural Mesothelioma—An Update
D. Stewart (2004)
10.1136/thorax.56.4.250
Statement on malignant mesothelioma in the United Kingdom
T. British (2001)
10.1002/14651858.CD005574.PUB2
Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma.
J. Green (2007)
10.1016/S1470-2045(11)70149-8
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
T. Treasure (2011)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar